Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
January-2020 Volume 21 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
January-2020 Volume 21 Issue 1

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia

  • Authors:
    • Joon Ha Park
    • Ji Hyeon Ahn
    • Dae Won Kim
    • Tae‑Kyeong Lee
    • Cheol Woo Park
    • Young Eun Park
    • Jae‑Chul Lee
    • Hyang‑Ah Lee
    • Go Eun Yang
    • Moo‑Ho Won
    • Choong‑Hyun Lee
  • View Affiliations / Copyright

    Affiliations: Department of Anatomy, College of Korean Medicine, Dongguk University, Gyeongju, Gyeongbuk 38066, Republic of Korea, Department of Biomedical Science, Research Institute of Bioscience and Biotechnology, Hallym University, Chuncheon 24252, Republic of Korea, Department of Biochemistry and Molecular Biology, and Research Institute of Oral Sciences, College of Dentistry, Gangneung‑Wonju National University, Gangneung, Gangwon 25457, Republic of Korea, Department of Neurobiology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea, Department of Obstetrics and Gynecology, School of Medicine, Kangwon National University, Chuncheon, Gangwon 24341, Republic of Korea, Department of Radiology, Kangwon National University Hospital, Chuncheon, Gangwon 24289, Republic of Korea, Department of Pharmacy, College of Pharmacy, Dankook University, Cheonan, Chungcheongnam‑do 31116, Republic of Korea
    Copyright: © Park et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 107-114
    |
    Published online on: November 20, 2019
       https://doi.org/10.3892/mmr.2019.10828
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Nuclear receptor related 1 protein (Nurr1), a member of the nuclear receptor 4 family of orphan nuclear receptors, has been reported to display anti‑inflammatory properties. The present study investigated the alteration of Nurr1 immunoreactivity in the gerbil hippocampus proper following 5 min of transient global cerebral ischemia. In sham operated gerbils, Nurr1 immunoreactivity was observed in pyramidal neurons in all cornu ammonis 1‑3 (CA1‑3) subfields of the hippocampus proper. In ischemia‑operated gerbils, Nurr1 immunoreactivity was altered in the CA1 subfield. Nurr1 immunoreactivity in CA1 pyramidal neurons gradually decreased until 2 days post‑ischemia, and, at 4 days post‑ischemia, Nurr1 immunoreactivity was concentrated in CA1 pyramidal neurons. Additionally, Nurr1 immunoreactivity was newly expressed in microglia in the CA1 subfield at 4 days post‑ischemia. Conversely, in the CA2/3 subfield, time‑dependent alteration of Nurr1 immunoreactivity was not identified at any time following ischemia. These results indicated that the alteration of Nurr1 expression in the CA1 subfield in the hippocampus may be associated with the death of CA1 pyramidal neurons.

Introduction

The hippocampus, a part of the limbic system, has been known to be one of the most vulnerable regions in the brain following transient global cerebral ischemia (tgCI) (1). Especially, tgCI leads to selective neuronal death at a few days, which is called ‘delayed neuronal death, after a brief tgCI in the CA1 subfield among the four subfields (CA1-CA4) of the hippocampus proper, while the CA3 subfield is known as the most tolerant hippocampal subregion against tgCI (2,3). Until now, many studies have made an effort to explain the pathophysiology of tgCI-induced neuronal death/damage in the CA1 subfield (4–6); however, the precise underlying mechanisms of tgCI-induced selective and delayed neuronal death in the CA1 subfield have not been fully understood.

Nuclear receptor related 1 protein (Nurr1), also known as NR4A2, is a member of nuclear receptor 4 family of orphan nuclear receptors, and Nurr1 has been studied to be expressed in various types of neurons and glia in the central nervous system (7–11). The Nurr1 function has been known as a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells and participates in the development and maintenance of dopaminergic neurons in the mesencephalon (12–15). In the hippocampus, Nurr1 is expressed in pyramidal neurons in the stratum pyramidale of the hippocampus proper (CA1-CA3 subfields) (16).

Recent studies have suggested that Nurr1 in the hippocampus proper plays a major role in cognitive function and stress (10,17,18). Additionally, it has been demonstrated that Nurr1 can display neuroprotective and anti-inflammatory properties (9,19–22). Also, some studies have reported that Nurr1 expression is altered in rodent brains following cerebral ischemia (23–27). However, the expressional changes of Nurr1 in the hippocampus proper after tgCI have not been fully elucidated. In the present study, thus, we investigated the time-dependent changes of Nurr1 expression in the hippocampus proper after 5 min of tgCI in gerbils, which are an excellent animal model of tgCI (5,28).

Materials and methods

Experimental animals

Six-month old male Mongolian gerbils (body weight, 70–80 g) were obtained from the Experimental Animal Center, Kangwon National University, Chuncheon, Republic of Korea. Animal care and all experimental procedures were approved by Institutional Animal Care and Use Committee at Kangwon National University (approval no. KW-180124-1). We minimized numbers of the gerbils used in this study and the suffering caused by the procedures used in this experiment.

Induction of tgCI

As described in our published papers (29–32), the surgical procedure for tgCI was as follows. Briefly, gerbils (total n=103; 63 gerbils for histological analysis and 40 gerbils for western blot analysis) were anesthetized with a mixture of 2.5% isoflurane in 34% oxygen (O2) and 66% nitrous oxide (N2O). Blood flow to the brain was completely interrupted by bilateral common carotid artery occlusion (BCCAO) for 5 min by using aneurysm clips in order to confirm stop of blood flow in the central artery in retinae under an ophthalmoscope. Body temperature was controlled under normothermic (37±0.5°C) condition with a rectal temperature probe: Normothermia was controlled with a thermometric blanket before and during the surgery. Sham operated gerbils were subjected to the same procedure without BCCAO.

Preparation of histological sections

Brain sections containing the hippocampus were prepared from sham and ischemia operated gerbils (n=7 at each point in time) at designated times (6, 12 h, 1, 2, 3, 4, 7 and 10 days after tgCI). Brain sections from the sham operated gerbils (n=7) were prepared at 4 days after tgCI. As described in our published papers (29–32), the gerbils were intraperitoneally anaesthetized with sodium pentobarbital (60 mg/kg) (JW Pharm. Co., Ltd.) and perfused transcardially with 0.1 M phosphate-buffered saline (PBS) followed by 4% paraformaldehyde. The brains were removed, postfixed with the same fixative for 8 h and cryoprotected by soaking in a 30% sucrose solution for 12 h. The brain tissues were serially sectioned into 30-µm thickness of coronal sections in a cryostat (Leica).

Examination of delayed neuronal death

To examine tgCI-induced delayed neuronal death in the hippocampus proper, CV staining and Fluoro-Jade B (FJB) histofluorescence staining were performed by methods as we described previously (29,30). In brief, the sections were stained with solution of CV acetate (Sigma), which was dissolved at 1.0% (w/v) and contained 0.28% glacial acetic acid, for 2 min. And the stained sections were washed and dehydrated in ethanol series. For FJB histofluorescence, the sections were serially stained with a 1% sodium hydroxide solution, a 0.06% potassium permanganate solution and a 0.0004% FJB (Histochem) solution. The reacted sections were examined using an epifluorescent microscope (Carl Zeiss) equipped with a blue excitation light (450–490 nm) and a barrier filter.

Immunohistochemistry

As we described in our published papers (29–32), immunohistochemical staining for Nurr1 was performed as follows. In brief, the brain sections were incubated with mouse anti-Nurr1 (1:100, Thermo Fisher Scientific, Inc.) as primary antibody and exposed to biotinylated goat anti-mouse IgG and streptavidin peroxidase complex (Vector) as secondary antibody. Finally, the reacted sections were visualized with 3,3′-diaminobenzidine (in 0.1 M Tris-HCl buffer, pH 7.4).

In order to establish the specificity of Nurr1 immunoreaction, negative control test was done by using pre-immune serum instead of the primary antibody. The negative control showed no immunoreactivity in the immunostained tissues.

For the quantitative analysis of Nurr1 immunoreactivity, 6 sections were selected with 120-µm interval per animal, and digital images of Nurr1 immunoreactivity were captured with Axio Imager 2 microscope (Carl Zeiss) equipped with a digital camera (Axiocam; Carl Zeiss). According to our published method (31), the images were calibrated into an array of 512×512 pixels corresponding to a tissue area of 140×140 µm including the stratum pyramidale of the sham and ischemia operated gerbils. The density of all Nurr1-immunoreactive structures was evaluated as relative optical density (ROD) as follows. Optical density (RO) of all the Nurr1-immunoreactive structures were obtained after the transformation of the mean gray level using the formula: OD=log (256/mean gray level), and the OD of background was taken from the areas adjacent to the measured area. Finally, a ratio of the OD was calibrated as % (ROD) by using NIH Image 1.59 software.

Double immunofluorescence staining

To examine the cell type containing Nurr1 immunoreactivity, double immunofluorescence staining was performed after tgCI according to our published protocol (30,31). In brief, we used mouse anti-Nurr1 (1:40, Thermo Fisher Scientific, Inc.)/rabbit anti-NeuN (a marker for neurons; 1:800, Millipore), rabbit anti-ionized calcium-binding adapter molecule 1 (Iba-1, a marker for microglia; 1:100, Wako) or rabbit anti-glial fibrillary acidic protein (GFAP, a marker for astrocytes; 1:200, Millipore). The sections were incubated in the mixture of antisera and reacted in a mixture of Cy3-conjugated goat anti-mouse IgG (1:200; Jackson ImmunoResearch, West Grove, PA, USA) and FITC-conjugated goat anti-rabbit IgG (1:200; Jackson ImmunoResearch). The immunoreactions were observed under a confocal MS (LSM510 META NLO, Carl Zeiss).

Western blot analysis

Nurr1 protein level in the CA1 subfield were analyzed at designated times (6, 12 h, 1, 2, 4, 7 and 10 days after tgCI) using western blot method according to our published procedure (29,30). In brief, 5 animals at each point in time were intraperitoneally anaesthetized with sodium pentobarbital (60 mg/kg), and their brains were removed. The brains were serially and transversely cut into 400-µm thickness using a vibratome (Leica). Hippocampal CA1 fields were cut by using a surgical blade and homogenized in 50 mM PBS (pH 7.4) containing 0.1 mM ethylene glycol bis (2-aminoethyl ether)-N,N,N0,N0 tetraacetic acid (pH 8.0), 0.2% Nonidet P-40, 10 mM ethylendiamine tetraacetic acid (pH 8.0), 15 mM sodium pyrophosphate, 100 mM β-glycerophosphate, 50 mM NaF, 150 mM NaCl, 2 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride and 1 mM dithiothreitol (DTT). The homogenized tissues were centrifugated at 16,000 × g for 25 min, and protein levels were determined using a Micro BCA protein assay kit (Pierce Chemical). Aliquot containing total protein (20 mg) was boiled in loading buffer containing 150 mM Tris-HCI (pH 6.8), 6% SDS, 3 mM DTT, 0.3% bromophenol blue and 30% glycerol and loaded onto 10% polyacrylamide gel. The gel was transferred to nitrocellulose transfer membranes (Pall Crop.) after electrophoresis. The background of the membrane was reduced with 5% nonfat dry milk in PBS containing 0.1% Tween 20 for 40 min, and the membrane was reacted with mouse anti-Nurr1 (1:200; Thermo Fisher Scientific, Inc.), peroxidase-conjugated goat anti-mouse IgG and ECL kit. The loading control was carried out using mouse anti-β-actin (1:5,000) antibody. Western blot analysis using homogenates at all experimental time-points was performed simultaneously. Results of the western blotting were scanned, and the quantification of the bands was densitometrically analyzed using NIH Image 1.59 software. The quantification was represented by relative optical density (ROD). A ratio of the ROD was calibrated as %: The sham operated group was designated as 100%.

Statistical analysis

The data shown here represent the means ± SEM. Differences of the means among the groups were statistically analyzed by analysis of variance (ANOVA) with Duncan's post hoc test in order to elucidate ischemia-related differences among experimental groups. P<0.05 was considered to indicate a statistically significant difference.

Results

tgCI-induced delayed neuronal death

tgCI-induced delayed neuronal death in the hippocampus proper (CA1-3 subfields) was examined at 2 days and 4 days after tgCI using CV staining and FJB histofluorescence staining. In the sham group, cells in the CA1-3 subfields were easily stained with CV. In particular, pyramidal neurons of the stratum pyramidale of the CA1-3 subfields were large and pyramidal in shape (Fig. 1A, D and J). In the ischemia group, no difference in CV staining in the hippocampus proper was found at 2 days after tgCI, compared to the sham group (Fig. 1B, E and K). On the other hand, most of CV-positive pyramidal neurons in the stratum pyramidale of the CA1 subfield were dead at 4 days after tgCI (Fig. 1C and F). At this point of time, many FJB positive cells were observed in the stratum pyramidale of the CA1 subfield (Fig. 1I). However, CV-positive pyramidal neurons in the CA2/3 subfield were not damaged at 4 days after tgCI (Fig. 1C and L). In addition, any FJB positive cells were not found in the CA2/3 subfield (data not shown). This result is consistent with the results of our previous studies (29–31).

Figure 1.

CV and FJB histofluorescence staining in the gerbil hippocampus. (A-C) Low magnification image of CV staining in the gerbil hippocampus of the (A) sham and (B and C) ischemia groups. The squares in the CA1 and CA3 areas indicate the positions of the high magnification images in (D-F and J-L). (D-F) High magnification images of CV staining in the CA1 subfield of the (D) sham and (E and F) ischemia groups. CV-positive cells disappear (triangle) in the SP of the CA1 subfield at 4 days after tgCI. (G-I) High magnification images of FJB histofluorescence staining in the CA1 subfield of the (G) sham and (H and I) ischemia groups. Numerous FJB-positive cells were detected (triangle) in the SP of the CA1 subfield at 4 days after tgCI. (J-L) High magnification images of CV staining in the CA3 subfield of the (J) sham and (K and L) ischemia groups. CV-positive cells were intact in the CA3 subfield until 4 days after tgCI. SO, stratum oriens; SR, stratum radiatum. Scale bar, 400 µm (A-C) or 50 µm (D-L). CV, Cresyle violet; FJB, Fluoro-Jade B; tgCI, transient global cerebral ischemia; SO, stratum oriens; SR, stratum radiatum; SP, stratum pyramidale; CA, cornu ammonis.

tgCI-induced change of Nurr1 immunoreactivity in CA1 subfield

In the sham group, Nurr1 immunoreactivity was primarily shown in pyramidal neurons of the stratum pyramidale of the hippocampus proper (CA1-3 subfields) (Fig. 2A). In the CA1 subfield of the ischemia group, Nurr1 immunoreactivity in the CA1 pyramidal neurons began to decrease from 6 h after tgCI, and the immunoreactivity was gradually decreased with a time-dependent manner until 3 days after tgCI (Fig. 2B-F and J). Especially, at 2 and 3 days after tgCI, Nurr1 immunoreactivity in the CA1 pyramidal neurons was hardly detected (Fig. 2E and F). However, Nurr1 immunoreactivity was increased in the CA1 subfield at 4 and 7 days after tgCI (Fig. 2G, H and J). At these points of time, Nurr1-immunoreactive cells were observed in the stratum pyramidale of the CA1 subfield, and Nurr1 immunoreactivity was detected in non-pyramidal cells of the stratum oriens and radiatum in the CA1 subfield (Fig. 2G and H). And then, Nurr1 immunoreactivity was decreased in the CA1 subfield at 10 days after tgCI (Fig. 2I and J).

Figure 2.

Immunoreactivity of Nurr1 in the CA1 subfield of the (A) sham and (B-I) ischemia groups. Nurr1 immunoreactivity in the sham group was observed in CA1 pyramidal neurons (triangle). In the ischemia group, Nurr1 immunoreactivity in CA1 pyramidal neurons gradually decreased until 2 days and 3 days post-ischemia. At 4 days and 7 days post-ischemia, Nurr1 immunoreactivity was increased in non-pyramidal cells (arrows) of the CA1 subfield. Subsequently, Nurr1 immunoreactivity in the CA1 subfield was decreased again at 10 days after tgCI. Scale bar, 50 µm. (J) ROD as % of Nurr1-immunoreactive structures in the CA1 subfield after tgCI (n=7 at each time point). Bars indicate the means ± SEM. *P<0.05 vs. sham group; †P<0.05 vs. previous time point. tgCI, transient global cerebral ischemia; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum; CA, cornu ammonis; Nurr1, nuclear receptor related 1 protein.

Nurr1 expression in neurons or microglia

As shown in Fig. 2A, Nurr1 immunoreactivity was observed in the stratum pyramidale of the CA1 subfield of the sham operated group. To confirm whether Nurr1 is expressed in pyramidal neurons, double immunofluorescence staining was performed for Nurr1/NeuN (neurons). We found that Nurr1-immunoreactive cells were colocalized with NeuN-immunoreactive neurons in the CA1 subfield of the sham operated group (Fig. 3A-C).

Figure 3.

Double immunofluorescence staining for (A, D and G) Nurr1 (red), (B) NeuN (green) for neurons, (E) Iba-1 (green) for microglia or (H) GFAP (green) for astrocytes, and (C, F and I) merged images in the CA1 subfield. Nurr1-immunoreactive cells were colocalized with NeuN-immunoreactive neurons in the sham operated group. At 4 days after tgCI, Nurr1-immunoreactive cells expressed Iba-1 immunoreactivity (arrows) in the CA1 subfield of the ischemia operated group. Scale bar, 50 µm. tgCI, transient global cerebral ischemia; SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum; CA, cornu ammonis; Nurr1, nuclear receptor related 1 protein; NeuN, neuronal nuclei; Iba-1, allograft inflammatory factor 1.

In addition, as shown in Fig. 2F and G, Nurr1 immunoreactivity was newly expressed in non-pyramidal cells in the CA1 subfield at 4 days after tgCI. To identify the cell type, double immunofluorescence staining was performed for Nurr1/Iba-1 (microglia) and Nurr1/GFAP (astrocytes). We found that Nurr1-immunoreactive cells were colocalized with Iba-1-immunoreactive microglia, not with GFAP-immunoreactive astrocytes, in the CA1 subfield at 4 days after tgCI (Fig. 3D-I).

tgCI-induced change of Nurr1 immunoreactivity in CA2/3 subfield

Unlike the tgCI-induced change of Nurr1 immunoreactivity in the CA1 subfield, Nurr1 immunoreactivity in the CA2/3 subfield was not significantly changed at any times after tgCI (Fig. 4A-D).

Figure 4.

Immunoreactivity of Nurr1 in the CA3 subfield of the (A) sham and (B and C) ischemia groups. Nurr1 immunoreactivity in CA3 pyramidal neurons was not altered at (B) 2 and (C) 4 days following tgCI. Scale bar, 50 µm. (D) ROD as % of Nurr1-immunoreactive structures in the CA3 subfield after tgCI (n=7 at each time point). Bars indicate the means ± SEM. SO, stratum oriens; SP, stratum pyramidale; SR, stratum radiatum; Nurr1, nuclear receptor related 1 protein; CA, cornu ammonis; tgCI, transient global cerebral ischemia.

tgCI-induced change of Nurr1 protein level

Nurr1 protein level in the CA1 field was significantly changed with time after tgCI (Fig. 5), showing that the pattern of change of Nurr1 protein level was similar to that observed in the immunohistochemical data. Nurr1 protein level was significantly decreased at 6 h after tgCI compared to that of the sham operated group, and it was gradually decreased until 2 days after tgCI. At 4 days after tgCI, Nurr1 protein level was significantly increased, compared to that at 2 days after tgCI. At 7 days after tgCI, Nurr1 protein level was not different from that at 4 days after tgCI. And then, Nurr1 protein level was significantly decreased at 10 days after tgCI, compared to that at 7 days after tgCI.

Figure 5.

Western blot analysis of Nurr1 in the cornu ammonis 1 subfield of the sham-operated and ischemia-operated gerbils. ROD as % value of immunoblot band is represented (n=5 at each time point). *P<0.05 vs. sham group; †P<0.05 vs. previous time point. Bars indicate the means ± SEM. Nurr1, nuclear receptor related 1 protein.

Discussion

In this study, we examined neuronal death in the CA1 subfield after tgCI and found that CA1 pyramidal neurons did not die until 2 days after tgCI; however, CA1 pyramidal neurons died at 4 days post-tgCI. On the other hand, pyramidal neurons in the CA3 subfield did not die at any time after tgCI. These findings are consistent with results of previous studies (30,32).

Some previous studies have reported that brain ischemic insults cause changes of Nurr1 expression in various rodent models of cerebral ischemia (23,25,27). However, it is unclear if Nurr1 has a neuroprotective or detrimental effect against cerebral ischemia injury. It has been reported that a level of Nurr1 mRNA increased in the cerebral cortex following permanent middle cerebral artery occlusion (MCAO) in rats (25). They have also shown that Nurr1 mRNA is induced in pyramidal neurons of the rat hippocampal CA1 and CA3 subfields at 1 h after ischemic insult induced by MCAO (25). Recently, Zhang and Yu (27) have reported that protein expression and mRNA transcription of Nurr1 are significantly enhanced in the mouse brain following transient focal ischemia by MCAO, showing that the infarct volume is significantly reduced in Nurr1 knockout mice, compared with wild-type mice, after transient focal ischemia. They have urged that an increase of Nurr1 is associated with the progression of cerebral ischemia-reperfusion injury and that upregulated Nurr1 is involved in neuronal apoptosis and mitochondrial injury (27). Conversely, other previous studies have reported that cerebral ischemic insults decrease Nurr1 expression in brains (23,24,26). Erdo et al (23) have demonstrated that Nurr1 protein expression is down-regulated in the ipsilateral basal ganglia after transient focal ischemia induced by MCAO in mice. Additionally, it has been reported that Nurr1 mRNA expression is not changed in the pyramidal cell layer in the CA1 subfield of the gerbil hippocampus until 24 h after 5 min of tgCI, and then decreased at 72 h after tgCI (24). Recently, Xie et al (26) have reported that mRNA and protein levels of Nurr1 begin to decrease immediately after ischemic damage, reaching a minimum at 12 h and increase at 48 h in the rat brain including the hippocampus following transient MCAO. They have also shown that increased expression of Nurr1 can inhibit TNF-α expression in microglia, reduce ischemia-induced neuroinflammatory and cytotoxic response in neurons, and decrease infarct volume at an early stage after transient MCAO (26). In this study, we found that Nurr1 immunoreactivity, which was shown in pyramidal neurons of the CA1 subfield, gradually decreased with a time-dependent manner after tgCI, and that Nurr1 immunoreactivity in the CA1 pyramidal neurons was markedly weak at 2 and 3 days after tgCI. In addition, Nurr1 protein expression in the CA1 subfield was gradually decreased until 2 days after tgCI. However, we found that tgCI-induced change of Nurr1 immunoreactivity in the CA3 subfield was not shown at any time after tgCI. It has been reported that CA3 subfield is known to be a tolerant subfield following tgCI (3,29). Thus, it can be postulated that tgCI-induced reduction of Nurr1 expression in pyramidal neurons of the CA1 subfield may be closely involved with a process of the tgCI-induced death of CA1 pyramidal neurons.

In the present study, we first found that Nurr1 immunoreactivity was detected in non-pyramidal cells in the strata oriens and radiatum of the CA1 subfield at 4 days after tgCI. We examined the type of these non-pyramidal cells and found that they were microglia. It has been reported that Nurr1 expression in microglia is regulated in response to inflammation (33). Additionally, it has well been known that Nurr1 can attenuate expressions of proinflammatory and neurotoxic mediators in microglia through its ability to decrease NFκB activation (8,9,20). Additionally, some studies have suggested that beneficial effects of microglia, such as removal of cell debris and production of neurotrophic factors, are effectively played in the ischemic brain regions following ischemic insults (34,35). Thus, it is likely that newly expressed Nurr1 in microglia in strata oriens and radiatum of the CA1 subfield may be related with a beneficial effect of microglia following tgCI.

In summary, Nurr1 immunoreactivity was significantly changed in the CA1 subfield, not the CA3 subfield, following tgCI, and Nurr1 immunoreactivity was newly expressed in microglia of ischemic CA1 subfield at 4 days after tgCI. These results indicate that tgCI-induced alteration of Nurr1 expression may be closely related with tgCI-induced neuronal death in the hippocampal CA1 subfield.

Acknowledgements

Not applicable.

Funding

The present study was carried out with the support of ‘Cooperative Research Program for Agriculture Science and Technology Development, Rural Development Administration, Republic of Korea (project no. PJ01321101), and was supported by the Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIP (grant no. NRF-2015M3A9B6066835), and by the National Research Foundation of Korea funded by the Ministry of Education (grant no. NRF-2017R1D1A1B03029311).

Availability of data and materials

All data generated or analyzed during the present study are included in this published article.

Authors' contributions

TKL, CWP and YEP performed the measurements. DWK, JCL, HAL and GEY analyzed and interpreted data. JHP, JHA, MHW and CHL made substantial contributions to conception and design, and were involved in drafting and revising the manuscript, and interpreting all data. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The protocol of this experiment was approved by Institutional Animal Care and Use Committee (IACUC) at Kangwon National University (approval no. KW-180124-1). This protocol adhered to guidelines from the current international laws and policies in the ‘Guide for the Care and Use of Laboratory Animals’.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Globus MY, Busto R, Martinez E, Valdes I, Dietrich WD and Ginsberg MD: Comparative effect of transient global ischemia on extracellular levels of glutamate, glycine, and gamma-aminobutyric acid in vulnerable and nonvulnerable brain regions in the rat. J Neurochem. 57:470–478. 1991. View Article : Google Scholar : PubMed/NCBI

2 

Kirino T: Delayed neuronal death in the gerbil hippocampus following ischemia. Brain Res. 239:57–69. 1982. View Article : Google Scholar : PubMed/NCBI

3 

Kirino T and Sano K: Selective vulnerability in the gerbil hippocampus following transient ischemia. Acta Neuropathol. 62:201–208. 1984. View Article : Google Scholar : PubMed/NCBI

4 

Kim H, Ahn JH, Song M, Kim DW, Lee TK, Lee JC, Kim YM, Kim JD, Cho JH, Hwang IK, et al: Pretreated fucoidan confers neuroprotection against transient global cerebral ischemic injury in the gerbil hippocampal CA1 area via reducing of glial cell activation and oxidative stress. Biomed Pharmacother. 109:1718–1727. 2019. View Article : Google Scholar : PubMed/NCBI

5 

Lee JC, Park JH, Kim IH, Cho GS, Ahn JH, Tae HJ, Choi SY, Cho JH, Kim DW, Kwon YG, et al: Neuroprotection of ischemic preconditioning is mediated by thioredoxin 2 in the hippocampal CA1 region following a subsequent transient cerebral ischemia. Brain Pathol. 27:276–291. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Park JH, Kim YH, Ahn JH, Choi SY, Hong S, Kim SK, Kang IJ, Kim YM, Lee TK, Won MH and Lee CH: Atomoxetine protects against NMDA Receptor-mediated hippocampal neuronal death following transient global cerebral ischemia. Curr Neurovasc Res. 14:158–168. 2017. View Article : Google Scholar : PubMed/NCBI

7 

Arimatsu Y, Ishida M, Kaneko T, Ichinose S and Omori A: Organization and development of corticocortical associative neurons expressing the orphan nuclear receptor Nurr1. J Comp Neurol. 466:180–196. 2003. View Article : Google Scholar : PubMed/NCBI

8 

Kim CH, Han BS, Moon J, Kim DJ, Shin J, Rajan S, Nguyen QT, Sohn M, Kim WG, Han M, et al: Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease. Proc Natl Acad Sci USA. 112:8756–8761. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Saijo K, Winner B, Carson CT, Collier JG, Boyer L, Rosenfeld MG, Gage FH and Glass CK: A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell. 137:47–59. 2009. View Article : Google Scholar : PubMed/NCBI

10 

Xiao Q, Castillo SO and Nikodem VM: Distribution of messenger RNAs for the orphan nuclear receptors Nurr1 and Nur77 (NGFI-B) in adult rat brain using in situ hybridization. Neuroscience. 75:221–230. 1996. View Article : Google Scholar : PubMed/NCBI

11 

Zou J, Chen Z, Wei X, Chen Z, Fu Y, Yang X, Chen D, Wang R, Jenner P, Lu JH, et al: Cystatin C as a potential therapeutic mediator against Parkinson's disease via VEGF-induced angiogenesis and enhanced neuronal autophagy in neurovascular units. Cell Death Dis. 8:e28542017. View Article : Google Scholar : PubMed/NCBI

12 

Chu Y, Kompoliti K, Cochran EJ, Mufson EJ and Kordower JH: Age-related decreases in Nurr1 immunoreactivity in the human substantia nigra. J Comp Neurol. 450:203–214. 2002. View Article : Google Scholar : PubMed/NCBI

13 

Decressac M, Volakakis N, Bjorklund A and Perlmann T: NURR1 in Parkinson disease-from pathogenesis to therapeutic potential. Nat Rev Neurol. 9:629–636. 2013. View Article : Google Scholar : PubMed/NCBI

14 

Sakurada K, Ohshima-Sakurada M, Palmer TD and Gage FH: Nurr1, an orphan nuclear receptor, is a transcriptional activator of endogenous tyrosine hydroxylase in neural progenitor cells derived from the adult brain. Development. 126:4017–4026. 1999.PubMed/NCBI

15 

Yan W, Chen ZY, Chen JQ and Chen HM: BMP2 promotes the differentiation of neural stem cells into dopaminergic neurons in vitro via miR-145-mediated upregulation of Nurr1 expression. Am J Transl Res. 8:3689–3699. 2016.PubMed/NCBI

16 

Ahn JH, Lee JS, Cho JH, Park JH, Lee TK, Song M, Kim H, Kang SH, Won MH and Lee CH: Age-dependent decrease of Nurr1 protein expression in the gerbil hippocampus. Biomed Rep. 8:517–522. 2018.PubMed/NCBI

17 

Kim JI, Jeon SG, Kim KA, Kim YJ, Song EJ, Choi J, Ahn KJ, Kim CJ, Chung HY, Moon M and Chung H: The pharmacological stimulation of Nurr1 improves cognitive functions via enhancement of adult hippocampal neurogenesis. Stem Cell Res. 17:534–543. 2016. View Article : Google Scholar : PubMed/NCBI

18 

Montes P, Ruiz-Sanchez E, Calvillo M and Rojas P: Active coping of prenatally stressed rats in the forced swimming test: Involvement of the Nurr1 gene. Stress. 19:506–515. 2016. View Article : Google Scholar : PubMed/NCBI

19 

Barneda-Zahonero B, Servitja JM, Badiola N, Miñano-Molina AJ, Fadó R, Saura CA and Rodríguez-Alvarez J: Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival. J Biol Chem. 287:11351–11362. 2012. View Article : Google Scholar : PubMed/NCBI

20 

De Miranda BR, Popichak KA, Hammond SL, Jorgensen BA, Phillips AT, Safe S and Tjalkens RB: The Nurr1 Activator 1,1-Bis(3′-Indolyl)-1-(p-Chlorophenyl)Methane blocks inflammatory gene expression in BV-2 microglial cells by inhibiting nuclear factor κB. Mol Pharmacol. 87:1021–1034. 2015. View Article : Google Scholar : PubMed/NCBI

21 

Hammond SL, Safe S and Tjalkens RB: A novel synthetic activator of Nurr1 induces dopaminergic gene expression and protects against 6-hydroxydopamine neurotoxicity in vitro. Neurosci Lett. 607:83–89. 2015. View Article : Google Scholar : PubMed/NCBI

22 

Loppi S, Kolosowska N, Kärkkäinen O, Korhonen P, Huuskonen M, Grubman A, Dhungana H, Wojciechowski S, Pomeshchik Y, Giordano M, et al: HX600, a synthetic agonist for RXR-Nurr1 heterodimer complex, prevents ischemia-induced neuronal damage. Brain Behav Immun. 73:670–681. 2018. View Article : Google Scholar : PubMed/NCBI

23 

Erdo F, Trapp T, Mies G and Hossmann KA: Immunohistochemical analysis of protein expression after middle cerebral artery occlusion in mice. Acta Neuropathol. 107:127–136. 2004. View Article : Google Scholar : PubMed/NCBI

24 

Honkaniemi J and Sharp FR: Global ischemia induces immediate-early genes encoding zinc finger transcription factors. J Cereb Blood Flow Metab. 16:557–565. 1996. View Article : Google Scholar : PubMed/NCBI

25 

Honkaniemi J, States BA, Weinstein PR, Espinoza J and Sharp FR: Expression of zinc finger immediate early genes in rat brain after permanent middle cerebral artery occlusion. J Cereb Blood Flow Metab. 17:636–646. 1997. View Article : Google Scholar : PubMed/NCBI

26 

Xie X, Peng L, Zhu J, Zhou Y, Li L, Chen Y, Yu S and Zhao Y: miR-145-5p/Nurr1/TNF-a Signaling-induced microglia activation regulates neuron injury of acute cerebral Ischemic/reperfusion in rats. Front Mol Neurosci. 10:3832017. View Article : Google Scholar : PubMed/NCBI

27 

Zhang Z and Yu J: Nurr1 exacerbates cerebral ischemia-reperfusion injury via modulating YAP-INF2-mitochondrial fission pathways. Int J Biochem Cell Biol. 104:149–160. 2018. View Article : Google Scholar : PubMed/NCBI

28 

Ginsberg MD and Busto R: Rodent models of cerebral ischemia. Stroke. 20:1627–1642. 1989. View Article : Google Scholar : PubMed/NCBI

29 

Ahn JH, Shin MC, Kim DW, Kim H, Song M, Lee TK, Lee JC, Kim H, Cho JH, Kim YM, et al: Antioxidant properties of fucoidan alleviate acceleration and exacerbation of hippocampal neuronal death following transient global cerebral ischemia in high-fat diet-induced obese gerbils. Int J Mol Sci. 20(pii): E5542019. View Article : Google Scholar : PubMed/NCBI

30 

Park JH, Noh Y, Kim SS, Ahn JH, Ohk TG, Cho JH, Lee TK, Kim H, Song M, Lee JC, et al: Time-course changes and new expressions of MIP-3a and its receptor, CCR6, in the gerbil hippocampal CA1 area following transient global cerebral ischemia. Neurochem Res. 43:2102–2110. 2018. View Article : Google Scholar : PubMed/NCBI

31 

Park JH, Shin BN, Ahn JH, Cho JH, Kim IH, Kim DW, Won MH, Hong S, Cho JH and Lee CH: Ischemia-induced changes of PRAS40 and p-PRAS40 immunoreactivities in the gerbil hippocampal CA1 region after transient cerebral ischemia. Cell Mol Neurobiol. 36:821–828. 2016. View Article : Google Scholar : PubMed/NCBI

32 

Park JH, Park CW, Ahn JH, Choi SY, Shin MC, Cho JH, Lee TK, Kim IH, Cho JH, Lee JC, et al: Neuroprotection and reduced gliosis by pre- and post-treatments of hydroquinone in a gerbil model of transient cerebral ischemia. Chem Biol Interact. 278:230–238. 2017. View Article : Google Scholar : PubMed/NCBI

33 

Lallier SW, Graf AE, Waidyarante GR and Rogers LK: Nurr1 expression is modified by inflammation in microglia. Neuroreport. 27:1120–1127. 2016. View Article : Google Scholar : PubMed/NCBI

34 

Lu YZ, Lin CH, Cheng FC and Hsueh CM: Molecular mechanisms responsible for microglia-derived protection of Sprague-Dawley rat brain cells during in vitro ischemia. Neurosci Lett. 373:159–164. 2005. View Article : Google Scholar : PubMed/NCBI

35 

Stoll G and Jander S: The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol. 58:233–247. 1999. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Park JH, Ahn JH, Kim DW, Lee TK, Park CW, Park YE, Lee JC, Lee HA, Yang GE, Won MH, Won MH, et al: Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia. Mol Med Rep 21: 107-114, 2020.
APA
Park, J.H., Ahn, J.H., Kim, D.W., Lee, T., Park, C.W., Park, Y.E. ... Lee, C. (2020). Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia. Molecular Medicine Reports, 21, 107-114. https://doi.org/10.3892/mmr.2019.10828
MLA
Park, J. H., Ahn, J. H., Kim, D. W., Lee, T., Park, C. W., Park, Y. E., Lee, J., Lee, H., Yang, G. E., Won, M., Lee, C."Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia". Molecular Medicine Reports 21.1 (2020): 107-114.
Chicago
Park, J. H., Ahn, J. H., Kim, D. W., Lee, T., Park, C. W., Park, Y. E., Lee, J., Lee, H., Yang, G. E., Won, M., Lee, C."Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia". Molecular Medicine Reports 21, no. 1 (2020): 107-114. https://doi.org/10.3892/mmr.2019.10828
Copy and paste a formatted citation
x
Spandidos Publications style
Park JH, Ahn JH, Kim DW, Lee TK, Park CW, Park YE, Lee JC, Lee HA, Yang GE, Won MH, Won MH, et al: Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia. Mol Med Rep 21: 107-114, 2020.
APA
Park, J.H., Ahn, J.H., Kim, D.W., Lee, T., Park, C.W., Park, Y.E. ... Lee, C. (2020). Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia. Molecular Medicine Reports, 21, 107-114. https://doi.org/10.3892/mmr.2019.10828
MLA
Park, J. H., Ahn, J. H., Kim, D. W., Lee, T., Park, C. W., Park, Y. E., Lee, J., Lee, H., Yang, G. E., Won, M., Lee, C."Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia". Molecular Medicine Reports 21.1 (2020): 107-114.
Chicago
Park, J. H., Ahn, J. H., Kim, D. W., Lee, T., Park, C. W., Park, Y. E., Lee, J., Lee, H., Yang, G. E., Won, M., Lee, C."Altered Nurr1 protein expression in the hippocampal CA1 region following transient global cerebral ischemia". Molecular Medicine Reports 21, no. 1 (2020): 107-114. https://doi.org/10.3892/mmr.2019.10828
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team